Sense of smell deficits are common, linked to malnutrition in patients with kidney disease
Massachusetts General Hospital News Aug 07, 2017
In their report in the Journal of the American Society of Nephrology, the research team describes finding olfactory abnormalities in around 70 percent of patients with chronic kidney disease and 90 percent of those with end–stage renal disease and that more significant deficits were associated with factors indicating poor nutrition. A proof–of–concept trial of a potential treatment for these olfactory deficits had promising results.
ÂThe majority of patients with chronic kidney disease, particularly those in the more advanced stages who require dialysis, exhibited some degree of loss of their sense of smell, which correlated with reduced nutritional status, says Teodor Paunescu, PhD, of the MGH Division of Nephrology, corresponding author of the study.
Even though the sense of smell has a major contribution to the flavors of foods, most efforts to increase food intake in kidney disease patients have focused on the sense of taste and direct appetite stimulation.
The current study enrolled 161 participants  100 with end–stage kidney disease, all of whom were dialysis dependent; 36 with chronic disease not yet at the end stage, and 25 healthy controls. One test  the University of Pennsylvania Smell Identification test  determined participants ability to identify specific odors. Another test analyzed the level of an aroma that was required for detection by individual participants. Testing both for odor identification and got the odor detection threshold could determine whether abnormalities could be traced to olfactory neurons in the nasal passages or to the odor processing pathways in the brain.
Based on the odor identification tests, 69 percent of those with chronic kidney disease and 92 percent of those with end–stage disease had a significant reduction in their sense of smell. In the test determining odor detection thresholds, participants with end–stage kidney disease required a four times greater concentration of an aroma to be detected than did either those with chronic disease or control participants.
Despite the significant differences in olfactory ability between the three groups of participants, in all three participants ratings of their own sense of smell averaged about 80 percent on a scale of 0 to 100 percent, suggesting that most patients were not aware of having problems with their sense of smell. In all three groups, participants nutritional status  determined by a standard assessment of food intake, weight changes and gastrointestinal symptoms, along with measures of factors such as cholesterol and albumin, which reflects protein metabolism  correlated with their olfactory abilities.
To test a potential treatment for these olfactory deficits, the team enrolled seven dialysis–dependent, end–stage kidney disease patients in a pilot study of theophylline  a drug approved to treat asthma and emphysema and previously reported to reduce such deficits in patients without kidney disease. Participants self–administered daily intranasal doses of theophylline for six weeks and had follow–up tests every two weeks during the study period.
While the odor identification scores of two participants deteriorated, for the other five they increased an average of 5 percent, with the greatest improvement in any participant exceeding 10 percent, compared with scores at the trial outset. For three participants, the improvement was enough to move them up one category, such as from severe to moderate loss of smell or from moderate to mild.
ÂThe three patients in whom the odor detection threshold was improved by more than 10 percent after theophylline treatment were also the top three in terms of odor identification improvement, says Paunescu. ÂThe use of novel therapeutics to improve olfaction could be an innovative and effective way to prevent and alleviate malnutrition in kidney disease patients.Â
Go to Original
ÂThe majority of patients with chronic kidney disease, particularly those in the more advanced stages who require dialysis, exhibited some degree of loss of their sense of smell, which correlated with reduced nutritional status, says Teodor Paunescu, PhD, of the MGH Division of Nephrology, corresponding author of the study.
Even though the sense of smell has a major contribution to the flavors of foods, most efforts to increase food intake in kidney disease patients have focused on the sense of taste and direct appetite stimulation.
The current study enrolled 161 participants  100 with end–stage kidney disease, all of whom were dialysis dependent; 36 with chronic disease not yet at the end stage, and 25 healthy controls. One test  the University of Pennsylvania Smell Identification test  determined participants ability to identify specific odors. Another test analyzed the level of an aroma that was required for detection by individual participants. Testing both for odor identification and got the odor detection threshold could determine whether abnormalities could be traced to olfactory neurons in the nasal passages or to the odor processing pathways in the brain.
Based on the odor identification tests, 69 percent of those with chronic kidney disease and 92 percent of those with end–stage disease had a significant reduction in their sense of smell. In the test determining odor detection thresholds, participants with end–stage kidney disease required a four times greater concentration of an aroma to be detected than did either those with chronic disease or control participants.
Despite the significant differences in olfactory ability between the three groups of participants, in all three participants ratings of their own sense of smell averaged about 80 percent on a scale of 0 to 100 percent, suggesting that most patients were not aware of having problems with their sense of smell. In all three groups, participants nutritional status  determined by a standard assessment of food intake, weight changes and gastrointestinal symptoms, along with measures of factors such as cholesterol and albumin, which reflects protein metabolism  correlated with their olfactory abilities.
To test a potential treatment for these olfactory deficits, the team enrolled seven dialysis–dependent, end–stage kidney disease patients in a pilot study of theophylline  a drug approved to treat asthma and emphysema and previously reported to reduce such deficits in patients without kidney disease. Participants self–administered daily intranasal doses of theophylline for six weeks and had follow–up tests every two weeks during the study period.
While the odor identification scores of two participants deteriorated, for the other five they increased an average of 5 percent, with the greatest improvement in any participant exceeding 10 percent, compared with scores at the trial outset. For three participants, the improvement was enough to move them up one category, such as from severe to moderate loss of smell or from moderate to mild.
ÂThe three patients in whom the odor detection threshold was improved by more than 10 percent after theophylline treatment were also the top three in terms of odor identification improvement, says Paunescu. ÂThe use of novel therapeutics to improve olfaction could be an innovative and effective way to prevent and alleviate malnutrition in kidney disease patients.Â
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries